Alnylam Says Neurological Drug Passes Midstage Study
Alnylam Pharmaceuticals (ALNY) disclosed positive midstage testing results for its neurological drug patisiran, used to treat the potentially fatal disease transthyretin-mediated amyloidosis (TTM), a genetic disorder. The company said patisiran showed a mean 2.5-point reduction in a modified neuropathy impairment score after 12 months compared with an increase of 13 to 18 points in untreated patients. The study also stated that patisiran hit a